Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Tick Bites D064927 1 associated lipids
Chlamydial Pneumonia D061387 2 associated lipids
Reproductive Tract Infections D060737 1 associated lipids
Granulomatous Mastitis D058890 1 associated lipids
Trichiasis D058457 1 associated lipids
Asymptomatic Infections D058345 1 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Neglected Diseases D058069 3 associated lipids
Corneal Endothelial Cell Loss D055954 1 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Acute Lung Injury D055371 33 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Tracheobronchomalacia D055089 1 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Hyper-IgM Immunodeficiency Syndrome D053306 1 associated lipids
Pyomyositis D052880 2 associated lipids
Male Urogenital Diseases D052801 1 associated lipids
Tendinopathy D052256 3 associated lipids
Mucositis D052016 7 associated lipids
Pyloric Stenosis, Hypertrophic D046248 2 associated lipids
Moraxellaceae Infections D045828 3 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Communicable Diseases, Emerging D021821 3 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Multiple Sclerosis, Relapsing-Remitting D020529 7 associated lipids
Focal Nodular Hyperplasia D020518 1 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acquired Hyperostosis Syndrome D020083 1 associated lipids
Syncope, Vasovagal D019462 1 associated lipids
Pouchitis D019449 3 associated lipids
Pseudolymphoma D019310 1 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Abdominal Abscess D018784 2 associated lipids
Parasitemia D018512 5 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
T-Lymphocytopenia, Idiopathic CD4-Positive D018344 1 associated lipids
Furcation Defects D017823 1 associated lipids
Granuloma, Pyogenic D017789 2 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Pelvic Pain D017699 7 associated lipids
Aortic Aneurysm, Abdominal D017544 5 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Neisseriaceae Infections D016870 3 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Evans LA et al. Predicting injection site muscle damage. III: Evaluation of intramuscular formulations in the L6 cell model. 1996 Pharm. Res. pmid:8899856
Segreti J et al. In vitro activity of macrolides against intracellular Legionella pneumophila. 1996 Diagn. Microbiol. Infect. Dis. pmid:8902407
Gastearena I et al. Determination of the alpha1-acid glycoprotein binding of azithromycin in vitro by equilibrium dialysis. 1995 J Chemother pmid:8904095
Domingo S et al. Significance of environmental conditions (pH and serum) on the in vitro potency of azithromycin against Brucella melitensis. 1995 J Chemother pmid:8904096
Wendel TD 1-day azithromycin was as effective as 7-day doxycycline for nongonococcal urethritis syndrome in men. 1996 Nov-Dec ACP J. Club pmid:8912627
Luke DR et al. Safety, toleration, and pharmacokinetics of intravenous azithromycin. 1996 Antimicrob. Agents Chemother. pmid:8913468
Olsen KM et al. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. 1996 Antimicrob. Agents Chemother. pmid:8913469
Kuo CC et al. In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. 1996 Antimicrob. Agents Chemother. pmid:8913488
Aoyama T et al. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. 1996 J. Pediatr. pmid:8917247
O'Doherty B Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis. Paediatric Azithromycin Study Group. 1996 Eur. J. Clin. Microbiol. Infect. Dis. pmid:8922571
Griffith DE et al. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. 1996 Clin. Infect. Dis. pmid:8922790
Chulig I [Pharmacokinetic profile of azithromycin. Role in the treatment of genital Chlamydia infections]. 1996 Antibiot. Khimioter. pmid:8929112
Kuznetsova SM ["Sumamed in the treatment of urogenital infections"]. 1996 Antibiot. Khimioter. pmid:8929115
Skripkin IuK et al. [The problem of diagnosis and treatment of urogenital chlamydiosis in Russia]. 1996 Antibiot. Khimioter. pmid:8929120
Vasil'ev MM and Gazarian IIu [Clinico-laboratory evaluation of the effectiveness of azithromycin in the treatment of patients with Chlamydia and mixed Chlamydia-gonorrhea infections]. 1996 Antibiot. Khimioter. pmid:8929122
Meloni G and Meloni T Azithromycin vs. doxycycline for Mediterranean spotted fever. 1996 Pediatr. Infect. Dis. J. pmid:8933556
Jackson MA et al. Breakthrough sepsis in macrolide-resistant pneumococcal infection. 1996 Pediatr. Infect. Dis. J. pmid:8933560
Keysary A et al. The in-vitro anti-rickettsial activity of macrolides. 1996 J. Antimicrob. Chemother. pmid:8937968
Mein J et al. Donovanosis: sequelae of severe disease and successful azithromycin treatment. 1996 Int J STD AIDS pmid:8940677
Hoque S et al. Rhodococcus equi in CAPD-associated peritonitis treated with azithromycin. 1996 Nephrol. Dial. Transplant. pmid:8941608
Wiselka MJ et al. Response to oral and intravenous azithromycin in a patient with toxoplasma encephalitis and AIDS. 1996 J. Infect. pmid:8945715
Tansey MJ and Moe JB Severe neutropenia and prophylactic doses of rifabutin. 1996 Lancet pmid:8950911
Sefton AM et al. Azithromycin in the treatment of periodontal disease. Effect on microbial flora. 1996 J. Clin. Periodontol. pmid:8951627
Griffith DE et al. Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus--negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease. 1996 Clin. Infect. Dis. pmid:8953085
Brihmer C et al. Efficacy and safety of azithromycin versus lymecyline in the treatment of genital chlamydial infections in women. 1996 Scand. J. Infect. Dis. pmid:8953672
Van Bambeke F et al. Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity. 1996 Eur. J. Pharmacol. pmid:8957238
Montenez JP et al. Interaction of the macrolide azithromycin with phospholipids. II. Biophysical and computer-aided conformational studies. 1996 Eur. J. Pharmacol. pmid:8957239
Ripa S et al. A linear model for the pharmacokinetics of azithromycin in healthy volunteers. 1996 Nov-Dec Chemotherapy pmid:8957574
Peeling RW and Brunham RC Chlamydiae as pathogens: new species and new issues. 1996 Oct-Dec Emerging Infect. Dis. pmid:8969247
Cammarota G et al. Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. 1996 Aliment. Pharmacol. Ther. pmid:8971300
Pilotto A et al. Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. 1996 Aliment. Pharmacol. Ther. pmid:8971305
Andenaes K et al. Preoperative bacterial colonization and its influence on postoperative wound infections in plastic surgery. 1996 J. Hosp. Infect. pmid:8971618
Pozniak A and Nelson MR Against the proposition: all patients with advanced HIV disease should be offered rifabutin prophylaxis. 1996 Genitourin Med pmid:8976832
Schwartz RA et al. Bacillary angiomatosis in an HIV seronegative patient on systemic steroid therapy. 1996 Br. J. Dermatol. pmid:8977724
Vranes J Effect of subinhibitory concentrations of ceftazidime, ciprofloxacin, and azithromycin on the hemagglutination and adherence of uropathogenic Escherichia coli strains. 1996 May-Jun Chemotherapy pmid:8983884
Ichimiya T et al. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. 1996 May-Jun Chemotherapy pmid:8983885
Galova K et al. Multicenter randomized study of two once daily regimens in the initial management of community-acquired respiratory tract infections in 163 children: azithromycin versus ceftibuten. 1996 May-Jun Chemotherapy pmid:8983893
Akita H et al. [Bacteriological, pharmacokinetic and clinical evaluation of azithromycin in the pediatric field]. 1996 Jpn J Antibiot pmid:8986553
Nishimura T et al. [Clinical evaluation of azithromycin in pediatric infections]. 1996 Jpn J Antibiot pmid:8986554
Haruta T and Kobayashi Y [Therapeutic efficacy of azithromycin in pediatrics]. 1996 Jpn J Antibiot pmid:8986555
Kuroda Y and Ito M [Therapy with azithromycin in pediatric infections]. 1996 Jpn J Antibiot pmid:8986556
Okamoto T and Sekiguchi T [Clinical studies on azithromycin in pediatrics]. 1996 Jpn J Antibiot pmid:8986557
Toyonaga Y et al. [Pharmacokinetic and clinical evaluation of azithromycin using fine granules or capsules in the pediatric patients]. 1996 Jpn J Antibiot pmid:8988410
Okumura A and Kuno K [Pharmacokinetic and clinical evaluation of azithromycin in pediatrics]. 1996 Jpn J Antibiot pmid:8988411
Kobayashi Y et al. [Clinical study of a macrolide antibiotic, azithromycin, in pediatric patients]. 1996 Jpn J Antibiot pmid:8988412
Furukawa S and Okada T [A clinical evaluation of azithromycin in the treatment of pediatric infection]. 1996 Jpn J Antibiot pmid:8988413
Okada T et al. [Pharmacokinetic and clinical evaluations of azithromycin in the pediatric field]. 1996 Jpn J Antibiot pmid:8988414
Ishida Y et al. [Pharmacokinetic and clinical evaluation of azithromycin in pediatric infections]. 1996 Jpn J Antibiot pmid:8988415
Ohtsuka Y et al. [Pharmacokinetic and clinical studies on azithromycin in children]. 1996 Jpn J Antibiot pmid:8988416
Tseng AL et al. Azithromycin-related ototoxicity in patients infected with human immunodeficiency virus. 1997 Clin. Infect. Dis. pmid:8994766